Good morning, everyone, and how are you today? We are doing just fine, thank you, although running a bit behind schedule due to an uncooperative laptop that needs a version of Geritol, unfortunately. Nonetheless, we have diligently attempted to provide you with the latest assortment of interesting items as we prepare for another busy day. Hope all goes well and you conquer the world. And please do keep in touch. …

Insulin makers and pharmacy benefit managers sparred at a congressional hearing on Wednesday, blaming each other for escalating list prices of diabetes drugs and offering opposing policy prescriptions, STAT notes. But the blame game about the system frustrated both Democratic and GOP lawmakers of the House Energy and Commerce Committee oversight panel, who issued sharp warnings of reform, Modern Healthcare adds. And few clear solutions were offered by representatives, even as some sought drastic changes, according to Regulatory Focus.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy